CA2253913A1 - Sel de bismuth de sialyloligosaccharide et procede pour traiter et inhiber les ulceres gastriques et duodenaux avec cette substance - Google Patents

Sel de bismuth de sialyloligosaccharide et procede pour traiter et inhiber les ulceres gastriques et duodenaux avec cette substance Download PDF

Info

Publication number
CA2253913A1
CA2253913A1 CA002253913A CA2253913A CA2253913A1 CA 2253913 A1 CA2253913 A1 CA 2253913A1 CA 002253913 A CA002253913 A CA 002253913A CA 2253913 A CA2253913 A CA 2253913A CA 2253913 A1 CA2253913 A1 CA 2253913A1
Authority
CA
Canada
Prior art keywords
oligosaccharide
galactose
group
stomach
bismuth salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002253913A
Other languages
English (en)
Inventor
Herbert Swarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neose Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2253913A1 publication Critical patent/CA2253913A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédé pour traiter et/ou inhiber les ulcères gastriques et duodénaux, comprenant l'administration d'une composition pharmaceutique contenant un sel de bismuth d'un oligosaccharide défini par la formule (I): (NeuAc-$(a)(2-3)-pGal-.beta.(1)-(-X-)¿m?-(-Y-)¿n?-)¿p?-Z dans laquelle X = une laison chimique ou un groupe capable de lier la p galactose soit au groupe de liaison Y soit au support multivalent Z; dans laquelle l'oxygène glycosidique C¿1? de galactose peut être remplacé par N, S ou C; Y = un groupe de liaison; Z = un support multivalent; m = 0 ou 1; n = 0 ou 1; et p = un nombre entier de 2-1000. L'invention propose également un procédé pour traiter et/ou inhiber les ulcères gastriques et duodénaux par l'administration d'une composition pharmaceutique comprenant un sel de bismuth d'un oligosaccharide défini par la formule (III) (NeuAc-.alpha.(2-3)-pGal-.beta.(1)-A dans laquelle A = un groupe capable de se lier avec la p galactose et dans laquelle l'oxygène glycosidique C¿1? de galactose peut être remplacé par N, S ou C.
CA002253913A 1996-05-03 1997-04-28 Sel de bismuth de sialyloligosaccharide et procede pour traiter et inhiber les ulceres gastriques et duodenaux avec cette substance Abandoned CA2253913A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1676596P 1996-05-03 1996-05-03
US60/016,765 1996-05-03

Publications (1)

Publication Number Publication Date
CA2253913A1 true CA2253913A1 (fr) 1997-11-13

Family

ID=21778853

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002253913A Abandoned CA2253913A1 (fr) 1996-05-03 1997-04-28 Sel de bismuth de sialyloligosaccharide et procede pour traiter et inhiber les ulceres gastriques et duodenaux avec cette substance

Country Status (6)

Country Link
EP (1) EP0918526A1 (fr)
JP (1) JP2000509714A (fr)
KR (1) KR20000010732A (fr)
AU (1) AU710576B2 (fr)
CA (1) CA2253913A1 (fr)
WO (1) WO1997041875A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011403A (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
EP1411952B1 (fr) * 2001-06-29 2009-04-22 Glykos Finland Oy Utilisation d'au moins une substance glyco-inhibitrice contre les maladies contagieuses
JP5014018B2 (ja) * 2006-10-18 2012-08-29 旭化成ケミカルズ株式会社 ピロリ菌の抑制剤または静菌剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
WO1994003184A1 (fr) * 1992-07-31 1994-02-17 Neose Pharmaceuticals, Inc. Compositions destinees a traiter et inhiber les ulceres gastriques et duodenaux
AU709149B2 (en) * 1994-03-02 1999-08-19 Neose Technologies, Inc. Method for treating and inhibiting gastric and duodenal ulcers

Also Published As

Publication number Publication date
WO1997041875A1 (fr) 1997-11-13
AU2732697A (en) 1997-11-26
JP2000509714A (ja) 2000-08-02
AU710576B2 (en) 1999-09-23
KR20000010732A (ko) 2000-02-25
EP0918526A1 (fr) 1999-06-02

Similar Documents

Publication Publication Date Title
US5883079A (en) Method for inhibiting H. pylori infection in mammalian tissue
Vishwanath et al. Tracheobronchial mucin receptor for Pseudomonas aeruginosa: predominance of amino sugars in binding sites
KR19990022658A (ko) 올리고사카라이드 화합물에 의한 박테리아 저해물질
MXPA96003403A (en) Treatment of diarrhea associated with antibioti
WO1994003184A1 (fr) Compositions destinees a traiter et inhiber les ulceres gastriques et duodenaux
RU2283115C2 (ru) Новые вещества, связывающиеся с helicobacter pylori, и их применение
RU2306140C2 (ru) НОВЫЕ РЕЦЕПТОРЫ ДЛЯ Helicobacter pylori И ИХ ПРИМЕНЕНИЕ
AU709149B2 (en) Method for treating and inhibiting gastric and duodenal ulcers
JP2006511497A (ja) ヘリコバクターピロリに対する高親和性レセプターおよびその用途
CN100338085C (zh) 唾液酸化的碳水化合物
AU710576B2 (en) Bismuth salt of sialyloligosaccharide and a method for treating and inhibiting gastric and duodenal ulcers with same
US20050220819A1 (en) Novel binding epitopes for helicobacter pylori and use thereof
WO1998026662A1 (fr) Composes et methodes pour traiter et prevenir les maladies bacteriennes et virales
JP2010532388A (ja) ポリシアル酸脱ｎ−アセチラーゼの阻害剤及びその使用方法
MXPA98009158A (en) Salt of bismuto de sialiloligosacarido and a metodopara treat and inhibit gastric and duodenal ulceras with the mi
JP2003535965A5 (fr)
JP2003535965A (ja) インフルエンザウイルス結合性シアル化オリゴ糖含有物質およびその用途
EP1169044A1 (fr) Structures glucidiques de n-acetyl lactosamine fucosyle sialyle permettant d'inhiber l'adhesion bacterienne
WO2004065400A1 (fr) Nouveaux epitopes de liaison a helicobacter pylori et utilisation desdits epitopes
US20020173483A1 (en) Chlamydia oligosaccharides
KR20010022739A (ko) 헬리코박터 필로리의 정착 저해제
Simon Section Review: Biologicals & Immunologicals: Complex carbohydrates in development as human pharmaceuticals
JP2004002239A (ja) ＴＮＦ−α産生抑制剤
HISANO et al. Influence of Macrolide Antibiotics on Co-stimulatory Molecule Expression on Mouse Splenic B-lymphocytes in vitro

Legal Events

Date Code Title Description
FZDE Dead